Bone mineral density improvement after one year of treatment with etanercept in patients with juvenile idiopathic arthritis
- Standort
-
Deutsche Nationalbibliothek Frankfurt am Main
- ISSN
-
1546-0096
- Umfang
-
Online-Ressource
- Sprache
-
Englisch
- Anmerkungen
-
online resource.
- Erschienen in
-
Bone mineral density improvement after one year of treatment with etanercept in patients with juvenile idiopathic arthritis ; volume:6 ; number:1 ; day:15 ; month:9 ; year:2008 ; pages:1-2 ; date:9.2008
Pediatric rheumatology ; 6, Heft 1 (15.9.2008), 1-2, 9.2008
- Urheber
-
Susic, G.
Stojanovic, R.
Damjanov, N.
Vojinovic, J.
Vijatov, G.
- Beteiligte Personen und Organisationen
-
SpringerLink (Online service)
- DOI
-
10.1186/1546-0096-6-S1-P90
- URN
-
urn:nbn:de:101:1-2019062203330062289630
- Rechteinformation
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Letzte Aktualisierung
-
14.01.2024, 00:19 MEZ
Datenpartner
Dieses Objekt wird bereitgestellt von:
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Beteiligte
- Susic, G.
- Stojanovic, R.
- Damjanov, N.
- Vojinovic, J.
- Vijatov, G.
- SpringerLink (Online service)
Ähnliche Objekte (12)
Fecal microbiota in children with juvenile idiopathic arthritis treated with methotrexate or etanercept
The efficacy and safety profile of biologic therapy with etanercept in juvenile idiopathic arthritis
Re-treatment with etanercept is as effective as the initial firstline treatment in patients with juvenile idiopathic arthritis
Etanercept for patients with juvenile idiopathic arthritis: drug levels and influence of concomitant methotrexate: observational study
The impact of a 2-year Etanercept administration on growth of patients with juvenile idiopathic arthritis
The lived experience of juvenile idiopathic arthritis in young people receiving etanercept
Disease status, reasons for discontinuation and adverse events in 1038 Italian children with juvenile idiopathic arthritis treated with etanercept
Evaluation of the disease course of Italian children with juvenile idiopathic arthritis treated with etanercept: preliminary results in 772 patients
PReS-FINAL-2144: Bone mineral status in patients with juvenile idiopathic arthritis after 12 months of treatment with etanercept
Etanercept improves pro-atherosclerotic biomarkers in children with juvenile idiopatic arthritis
Experience with etanercept, tocilizumab and interleukin-1 inhibitors in systemic onset juvenile idiopathic arthritis patients from the BIKER registry
Juvenile idiopathic arthritis treated with biological therapies
Fecal microbiota in children with juvenile idiopathic arthritis treated with methotrexate or etanercept
The efficacy and safety profile of biologic therapy with etanercept in juvenile idiopathic arthritis
Re-treatment with etanercept is as effective as the initial firstline treatment in patients with juvenile idiopathic arthritis
Etanercept for patients with juvenile idiopathic arthritis: drug levels and influence of concomitant methotrexate: observational study
The impact of a 2-year Etanercept administration on growth of patients with juvenile idiopathic arthritis
The lived experience of juvenile idiopathic arthritis in young people receiving etanercept
Disease status, reasons for discontinuation and adverse events in 1038 Italian children with juvenile idiopathic arthritis treated with etanercept
Evaluation of the disease course of Italian children with juvenile idiopathic arthritis treated with etanercept: preliminary results in 772 patients
PReS-FINAL-2144: Bone mineral status in patients with juvenile idiopathic arthritis after 12 months of treatment with etanercept
Etanercept improves pro-atherosclerotic biomarkers in children with juvenile idiopatic arthritis
Experience with etanercept, tocilizumab and interleukin-1 inhibitors in systemic onset juvenile idiopathic arthritis patients from the BIKER registry
Juvenile idiopathic arthritis treated with biological therapies
Fecal microbiota in children with juvenile idiopathic arthritis treated with methotrexate or etanercept
The efficacy and safety profile of biologic therapy with etanercept in juvenile idiopathic arthritis
Re-treatment with etanercept is as effective as the initial firstline treatment in patients with juvenile idiopathic arthritis
Etanercept for patients with juvenile idiopathic arthritis: drug levels and influence of concomitant methotrexate: observational study
The impact of a 2-year Etanercept administration on growth of patients with juvenile idiopathic arthritis
The lived experience of juvenile idiopathic arthritis in young people receiving etanercept
Disease status, reasons for discontinuation and adverse events in 1038 Italian children with juvenile idiopathic arthritis treated with etanercept
Evaluation of the disease course of Italian children with juvenile idiopathic arthritis treated with etanercept: preliminary results in 772 patients
PReS-FINAL-2144: Bone mineral status in patients with juvenile idiopathic arthritis after 12 months of treatment with etanercept
Etanercept improves pro-atherosclerotic biomarkers in children with juvenile idiopatic arthritis
Experience with etanercept, tocilizumab and interleukin-1 inhibitors in systemic onset juvenile idiopathic arthritis patients from the BIKER registry